THE TAPE
PSNL · Medical Laboratories · $1.6B

Personalis, Inc. Common Stock

$14.80▼ −5.79%
Last close
Relative strength
96RS
of 99, against every stock• 0 on the month
Powering up
Unconfirmed
+38.7%
six months against Medical Laboratories
52-week range
−21.7%
from the high
$4.96$18.89
Setup
vcpplayed out
−9.7%
against the pivot at $16.39
No report date on the calendar.
Growth REALProof PENDING
Quarter to Sep 30, revenue +77% on a year ago
11/16 O 15.60 H 15.69 L 14.78 Vol 6.4M
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

RS96
vs pivot−9.70%
Tightening1.72×
Dry-up1.89×
Up/down vol-0.13
From high22%
played out4 of 9checks
Powering up
Support and resistance
Support below
None within the last 120 sessions
Resistance above
$15.59
+5.3% · tested 5× · last 7 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 4.8 weeks and fell 30% from its ceiling at its deepest. The pivot is $16.39, and the stock closed 9.7% below it. Its relative strength rating is 96.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against its industry
-7.7%
Three months against its industry
-5.6%
Six months against its industry
+38.7%

Read against an equal-weighted index of Medical Laboratories, which is +58.5% against the S&P 500 over six months Fully aligned.

Also on
Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 8.9% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$80.8M
+76.6% year on year
Operating margin
-156.7%
Net margin
-147.7%
Free cash flow
$-107.7M
-6.8% of market cap
Price to sales
19.6×
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 4
Key takeaway
Real growth, but execution and cash generation are not yet proven.
Revenue
$25.6M
+14.5% QoQ · +76.6% YoY
Gross margin
—
Net income
−$33.8M
Loss
Free cash flow
−$30.1M
Burning · 3q runway

What the numbers say

  • Good: Revenue +76.6% year over year, +14.5% on the quarter
  • Weak: Net loss $34M, wider than $32M last quarter
  • Weak: Burning cash: operating cash flow -$27M, free cash flow -$30M, worse than -$30M last quarter · 3 quarters of cash at this burn
  • Weak: Growth externally funded: capex $3M against operating cash flow -$27M; share count +20.9% in a year
  • Good: Net cash $98M · cash $98M
Revenue by quarter
Free cash flow
Net income
shares +20.9% in a year · net cash $98.3M

What is not obvious

  • Weak: Stock compensation $4M added back against negative operating cash flow
  • Weak: Interest $36K a quarter against an operating loss: the debt is carried by the balance sheet, not operations
Final read
Growth: REAL · Economic proof: PENDING
Key question: Can the growth turn into durable profit and cash after its costs and financing?
The next test is operating profit: net loss $34M, wider than $32M last quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 2 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 bought new, 1 added.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Closed below its 20- and 50-day on heavy volumeTape · 2026-11-06
below 20d & 50d on 1.7x volume at 15.55
No measurable effect: stocks behave like random ones over the next three sessions (1,780 cases over 60 nights).
Reported resultsFiling · 2026-11-05
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Earnings date movedEvent · 2026-10-21
2026-11-02 -> 2026-11-10
No measurable effect: stocks behave like random ones over the next three sessions (2,989 cases over 51 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news

No headlines for this company in the last couple of weeks.

Insiders
Bought on the open market
0
Sold on the open market
14
$7,843,852 total

Sold: Hall Christopher M, Moore Stephen Michael, Chen Richard, Tachibana Aaron.

Not counted above: 10 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-11-03 Hall Christopher M · Chief Executive Officer, Directorsell29,112$462,007
2026-09-18 Moore Stephen Michael · SVP and Chief Legal Officersell2,068$33,543
2026-09-18 Chen Richard · President and CMOsell3,998$64,848
2026-09-18 Hall Christopher M · Chief Executive Officer, Directorsell7,459$120,985
2026-09-18 Tachibana Aaron · CFO AND COOsell2,931$47,541
2026-07-15 Chen Richard · President and CMOoption exercise100,000$244,000
2026-07-15 Chen Richard · President and CMOsell100,000$1,515,000
2026-07-09 Hall Christopher M · Chief Executive Officer, Directoroption exercise100,000$161,000

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

The geometry
falling wedge
Level · ceiling$15.46
Wrong below$14.71
Measured target · the shape's own height$16.68
Reward against risk1.6×
Lines closed · of the gap they started with40%
Through to the apex63%
Touches · swing points the lines are drawn through11 up · 11 down
Length12.2 weeks
descending triangle
Level · floor$15.70
Wrong above$16.15
Measured target · the shape's own height$14.47
Reward against risk2.8×
Lines closed · of the gap they started with68%
Through to the apex68%
Touches · swing points the lines are drawn through12 up · 11 down
Length12.2 weeks
squeeze
Level · ceiling$16.13
Wrong below$15.45
Measured target · a squeeze has no height to projectnone
Through to the apex16%
Leaning · and strengtheningdown
Length3.4 weeks

Leaning is where price has been sitting against its own range while the range was quiet. It is not a forecast of which way the range opens up, and this site has no measurement that would support one.

What lines up

4 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy0
Buy1
Hold4
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray
5w · 30%

The most recent of 3 completed bases.

Checking your subscription…

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Personalis, Inc. Common Stock (PSNL) — The Tape